Inhaled Furosemide for Transient Tachypnea of Newborn

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04397991

Enrollment

Registered

2020-05-21

Start date

2020-01-02

Completion date

2021-08-01

Last updated

2022-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory Morbidity

Brief summary

This is a randomized double blind clinical trial in which newborns with suspected Transient tachypnea of the newborn (TTN) will receive either furosemide or normal saline by nebulizer every 6 hours for 24 hours.

Interventions

OTHERFurosemide

Patients will receive nebulised furosemide solution 1 mg/kg

OTHERPlacebo

Patients will receive nebulised 0.9% saline

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

OTHER

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

1 Days to 1 Days

Healthy volunteers

Inclusion criteria

* Neonates with 34+0-39+0 gestational age * on the first day of life * with the clinical diagnosis of Transient Tachypnoea * need for CPAP \>6 hours to obtain the oxygen saturation \>92%

Exclusion criteria

* Systemic infection * Intubation and mechanical ventilation before Inclusion in the trail * Malformation and any other disease with disturb of respiratory system

Design outcomes

Primary

Measure	Time frame	Description
Percentage of patients with respiratory morbidity	24 hours	Neonatal respiratory morbidity will be assessed through oxygen saturation, respiratory rate and duration on Continuous positive airway pressure (CPAP)

Secondary

Measure	Time frame	Description
Length of hospital stay	15 days	Duration of hospital stay in days

Countries

Lebanon

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026